Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals

Table 5 The effect of the duration of interferon-based therapy for hepatitis C virus infection on the risk of end-stage renal disease and death

	IBT duration	ESRD events (%)	Adjusted HR1 (95%CI)	P value	Death events (%)	Adjusted HR2 (95%CI)	P value
Propensity score-matched HCV-infected CKD patients (n = 2410)	No (n = 1928)	134 (7.0)	1.00 (reference)		648 (33.6)	1.00 (reference)
	< 4 mo (n = 126)	3 (2.4)	0.79 (0.24-2.63)	0.70	23 (18.3)	1.18 (0.78-1.81)	0.44
	≥ 4 mo (n = 356)	2 (0.6)	0.14 (0.03-0.58)	0.007	38 (10.7)	0.57 (0.41-0.79)	0.001

¹Adjusted for all covariates (age per year, sex, comorbidity, ACEI/ARB, enrollee category, number of medical visits, and Charlson comorbidity index score) and competing mortality; ²Adjusted for all covariates (age per year, sex, comorbidity, ACEI/ARB, enrollee category, number of medical visits, and Charlson comorbidity index score). CKD: Chronic kidney disease; CI: Confidence interval; ACEI/ARB: Angiotensin converting enzyme inhibitor/angiotensin receptor blocker; ESRD: End-stage renal disease; HCV: Hepatitis C virus.